Nuance Pharma

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Vignette Gets Rights To BCMA×CD3 Bispec

It has been a topsy-turvy few weeks for Bavarian Nordic A/S since its respiratory syncytial virus (RSV) vaccine disappointed in a late-stage trial, but the Danish firm is on the up again following a

Bavarian Nordic A/S ’s respiratory syncytial virus (RSV) vaccine candidate, MVA-BN RSV, has missed the mark in the Phase III VANIR trial in older adults, but the firm is confident it can meet its fina

While most observers are waiting to see whether GSK plc and Pfizer Inc. 's respective respiratory syncytial virus (RSV) vaccines will secure US approval next month, Bavarian Nordic A/S is catchin